- Home
- GOSS vs EMF Comparison
GOSS vs EMF Comparison
Compare GOSS & EMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EMF
- Stock Information
- Founded
- GOSS 2015
- EMF 1987
- Country
- GOSS United States
- EMF United States
- Employees
- GOSS N/A
- EMF N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EMF Finance/Investors Services
- Sector
- GOSS Health Care
- EMF Finance
- Exchange
- GOSS Nasdaq
- EMF Nasdaq
- Market Cap
- GOSS 212.8M
- EMF 196.6M
- IPO Year
- GOSS 2019
- EMF N/A
- Fundamental
- Price
- GOSS $1.40
- EMF $13.31
- Analyst Decision
- GOSS Strong Buy
- EMF
- Analyst Count
- GOSS 5
- EMF 0
- Target Price
- GOSS $9.20
- EMF N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- EMF 29.3K
- Earning Date
- GOSS 03-04-2025
- EMF 01-01-0001
- Dividend Yield
- GOSS N/A
- EMF 6.16%
- EPS Growth
- GOSS N/A
- EMF N/A
- EPS
- GOSS N/A
- EMF N/A
- Revenue
- GOSS $105,322,000.00
- EMF N/A
- Revenue This Year
- GOSS N/A
- EMF N/A
- Revenue Next Year
- GOSS N/A
- EMF N/A
- P/E Ratio
- GOSS N/A
- EMF N/A
- Revenue Growth
- GOSS N/A
- EMF N/A
- 52 Week Low
- GOSS $0.50
- EMF $10.58
- 52 Week High
- GOSS $1.60
- EMF $12.67
- Technical
- Relative Strength Index (RSI)
- GOSS 67.09
- EMF 80.57
- Support Level
- GOSS $1.37
- EMF $12.56
- Resistance Level
- GOSS $1.55
- EMF $13.22
- Average True Range (ATR)
- GOSS 0.13
- EMF 0.13
- MACD
- GOSS 0.03
- EMF 0.09
- Stochastic Oscillator
- GOSS 75.81
- EMF 94.80
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.